WC
BCAX

Wexford Capital’s Bicara Therapeutics BCAX Stock Holding History

Wexford Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$261K – 342
2025
Q1 		$261K Hold
20,000
– – 0.07% 169
2024
Q4 		$348K Buy
+20,000
New +$416K 0.06% 126

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wexford Capital's BCAX Position: Q2 2025 in Review

Wexford Capital sold out of Bicara Therapeutics (BCAX) in Q2 2025, closing a stake of 20,000 shares — an estimated $261K sold.

Wexford Capital first reported a position in BCAX in Q4 2024 and held it in 2 quarters. The position peaked at $348K in Q4 2024. 106 funds tracked by Wall St. Rank hold BCAX as of Q2 2025.

  • Wexford Capital reported no remaining Bicara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 20,000 Bicara Therapeutics shares in Q2 2025, an estimated $261K.
  • Wexford Capital first reported a position in Bicara Therapeutics in Q4 2024 and held it in 2 quarters.
  • Wexford Capital's Bicara Therapeutics position peaked at $348K in Q4 2024.
  • 106 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.